The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers
ConclusionSGLT-2i in KTR is not associated with an increased risk of genital infection and UTI in diabetic KTR, even in the early posttransplant period. The use of SGLT-2i reduces proteinuria in KTR and has no adverse effects on allograft function at the 12-month follow-up.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Bone Graft | Diabetes | Endocrinology | Kidney Transplant | Kidney Transplantation | Proteinuria | Study | Transplant Surgery | Transplants | Urinary Tract Infections | Urology & Nephrology